Latest Drugs, Latest Approval in Platelet-stimulating agents

What are Platelet-stimulating agents?

Platelet-stimulating agents encourage the body to produce more platelets.

These agents may work by different mechanisms. They can stimulate megakaryocytes, precursors of platelets, to produce platelets faster than normal or they may act as c-mpl (TpoR) receptor agonists. The c-mpl (TpoR) receptor is a target for thrombopoietin, a hormone that stimulates development of megakaryocytes.

Platelet-stimulating agents are used to treat chronic idiopathic thrombocytopenic purpura.

Name Updated
Eltrombopag (Eltrombopag [ el-trom-boe-pag ]) 14-Aug-2023
Lusutrombopag (Lusutrombopag [ loo-soo-trom-boe-pag ]) 13-Aug-2023
Avatrombopag (Avatrombopag [ a-va-trom-boe-pag ]) 13-Aug-2023
Romiplostim (Romiplostim) 12-Aug-2023
Doptelet (Avatrombopag [ a-va-trom-boe-pag ]) 05-Aug-2023
Mulpleta (Lusutrombopag [ loo-soo-trom-boe-pag ]) 13-Jul-2023
Promacta (Eltrombopag [ el-trom-boe-pag ]) 11-Jul-2023
Nplate (Romiplostim [ rom-i-plos-tim ]) 11-Jul-2023